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The management of patients with advanced pancreatic cancer often requires a multi-disciplinary approach 
with individualised therapy. Addressing the underlying causes of several of the troublesome symptoms that 
are relatively unique to the pathophysiology of pancreatic cancer is crucial in order to optimise the function 
and comfort of people diagnosed with this poor prognosis cancer. Early recognition and response is likely to 
improve outcomes later in the course of the disease, but more work needs to be done to compare expectant 
and reactive approaches to the most troublesome symptoms in advanced pancreatic cancer. Given such 
a poor outlook, referral to a palliative care service that has an active, team-based approach that includes 
dietetics, gastroenterology, interventional pain expertise and liaison psychiatry is likely to deliver the best 
possible outcomes. Such programs need to be in centres with sufficient caseload to ensure that meaningful 
outcomes can be measured prospectively and these teams are also best placed to incorporate new knowledge 
and approaches as the evidence base continues to evolve.
Pancreatic cancer is the fifth most common cause of 
death due to cancer in Australia, and the rest of the 
western world. In 2011, the overall five year survival 
was 5.2% in Australia for patients diagnosed with 
pancreatic cancer. If Australian trends of incidence and 
mortality in pancreatic cancer mirror the United States, 
the implication is that the incidence of pancreatic cancer 
will increase over the next few decades to become 
one of the leading causes of cancer-related mortality 
in Australia.1 Approximately 80-85% of patients have 
unresectable disease at presentation,2 and this group of 
patients can expect to have a five-year survival of 3% 
in Australia.1 Therefore, patients with locally advanced 
pancreatic cancer may benefit from early referral to a 
palliative care service for symptom management.
Specific symptom management issues that 
relate to advanced prostate cancer
In the palliative care setting, patients with advanced 
cancer commonly experience symptoms such as pain, 
nausea and vomiting. However, advanced pancreatic 
cancer causes a number of other symptoms due to the 
anatomical location of the primary tumour and pattern 
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of metastatic spread, with infiltration of the liver and 
coeliac or splanchnic nodes. Advanced prostate cancer 
also predisposes patients to an increased risk of venous 
thrombo-embolism (VTE). 
Venous thrombo-embolism in pancreatic 
cancer
A diagnosis of cancer carries a hundred-fold increased 
risk of venous VTE compared with the healthy population. 
Pancreatic cancer has an increased incidence of VTE 
compared with all other cancer populations. The rate 
of presentation with VTE has recently been reported 
to be 11.6% at three months and 21.3% at 12 months 
after diagnosis in advanced pancreatic cancer.3 The 
increase in VTE risk is thought to be due to cancer 
cell over-expression of tissue factor and mucin, and 
this leads to a hypercoagulable state. Over-expression 
of tissue factor and mucin occur more frequently with 
primary tumours originating within the body and the tail 
of the pancreas than in the head. This may explain the 
increased incidence in VTE in body and tail tumours, 
and a worse prognosis in these patients.4 Where 
patients with advanced pancreatic cancer present with 
abdominal pain, inferior vena cava or splanchnic vein 
thrombosis should be considered in the differential 
cause.
The CLOT study in 2003 demonstrated that low 
molecular weight heparin (LWMH) dalteparin produced 
better overall survival and fewer bleeding events than 
warfarin. LMWH has been the gold standard treatment 
of VTE in cancer.5 Since then, rivaroxiban has been 
introduced to reduce the risk of stroke in atrial fibrillation. 
The advantages of rivaroxiban over LMWH and warfarin 
are that it is taken by tablet once a day and does not 
require any therapeutic monitoring. However, there 
have been no studies published to date that prove 
superiority of the use of rivaroxiban in the treatment of 
VTE in cancer patients. The role of primary prevention of 
VTE in advanced pancreatic cancer is being elucidated. 
The PROSPECT-CONKO 004 study showed that the 
greatest reduction in VTE events was in the first three 
months after patients commenced chemotherapy in 
combination with treatment with enoxaparin compared 
with chemotherapy alone.3 As expected, there was also 
an increased risk of major bleeding in the enoxaparin 
group (8.3% in the enoxaparin group vs 6.9% in 
the observation group). The study was not powered 
to determine the safety of enoxaparin in the trial 
conditions. Further studies are awaited to determine 
the role of thromboprophylaxis in the management of 
patients with advanced pancreatic cancer who have 
supportive care alone.
Pancreatic exocrine insufficiency
Pancreatic exocrine insufficiency (PEI) occurs as cells, 
which synthesise pancreatic enzymes, are either 
progressively destroyed by pancreatic cancer cells, or 
the main pancreatic duct is blocked by a tumour within 
the anatomical head of the pancreas, where the majority 
of tumours occur.6,7 This causes compression of the 
proximal pancreatic duct, and endoscopic stenting may 
be required.  Consultation with a gastroenterologist will 
determine the role for investigation with endoscopic 
retrograde cholangiopancreatography and insertion of 
a biliary stent. Untreated blockage at the head of the 
pancreas causes progressive loss of exocrine function 
of the pancreas, and patients will experience symptoms 
of PEI resulting in deterioration in the patient’s quality 
of life and overall survival.8,9 The incidence of PEI is 
estimated to be around 85% when patients present 
with pancreatic cancer.10
PEI occurs in other disorders of the pancreas such 
as cystic fibrosis, chronic pancreatitis and following 
pancreatic resection. PEI has been extensively 
studied in these non-malignant conditions, but not in 
advanced pancreatic cancer. Symptoms arise due to 
malabsorption of fat, and these include weight loss, 
diarrhoea, steatorrhoea, flatulence, abdominal pain 
and bloating. PEI may also cause fat-soluble vitamin 
deficiencies.
The mechanism for treating PEI in pancreatic cancer 
with pancreatic enzyme replacement therapy (PERT) 
was elucidated in a small study from the Mayo Clinic 
in 1983.11 Guidelines, based on studies with small 
numbers of patients, recommend the empiric treatment 
of symptomatic patients with PERT.7,12,13 Patients who 
have undergone pancreatic resection are prescribed 
PERT based on their risk of PEI.2 Yet patients who 
have advanced pancreatic cancer are not routinely 
evaluated for symptoms of PEI, referred to a dietitian 
or offered PERT.14 There is evidence that patients often 
try dietary fat restriction or other therapies to manage 
their symptoms, and have a variable degree of success 
in managing of PEI.15
The most commonly prescribed PERT is an encapsulated 
form of pancreatic enzymes derived from porcine 
pancreas. Its safety profile has been established in 
cystic fibrosis and chronic pancreatitis.16 Successful 
treatment with PERT requires education by a dietitian to 
explain the timing of medication with relation to meals. 
Individualised therapy may be required, including, for 
example, a change in dose or the addition of a proton 
pump inhibitor, which aids the activation of PERT if 
the gut pH is too low. Patients who are on treatment 
require monitoring and treatment algorithms have been 
published.17 Data on the success of treatment with 
PERT in advanced pancreatic cancer have not been 
published to date. For patients who have treatment 
failure, further investigation can exclude the presence 
of bacterial overgrowth.18
Cachexia in advanced pancreatic cancer
Cachexia arises as a consequence of release of 
systemic cytokines and PEI in advanced pancreatic 
cancer, and is known to have an adverse effect upon 
overall survival of patients who present with resectable 
pancreatic cancer.9 This study compared patients who 
had cachexia at presentation with pancreatic cancer 
and those who did not, and found that patients who 
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cachexia at presentation had poorer overall survival at 
12 months post-operatively compared with patients 
who did not. It has been demonstrated that PERT can 
prevent weight loss in advanced pancreatic cancer,19 
but no definitive studies have established that there is 
a survival advantage with PERT. The hypothesis that 
treatment of cachexia and PEI in advanced pancreatic 
cancer may result in improvement of patient quality of 
life and prognosis is unproven in clinical trials.
Pain and pancreatic cancer
Pain management is a challenging issue and affects 
50-70% of patients who are diagnosed with pancreatic 
cancer. The principles of management have not 
changed significantly since Russell Portenoy published 
an article on this area in 1996.20 Pain caused by 
pancreatic cancer can be multi-factorial in aetiology 
and accurate diagnosis is essential in successful 
management. Perception of pain may be increased if 
depression coexists in advanced cancer. The incidence 
of depression in patients who have been diagnosed 
with pancreatic cancer has been reported to be as 
high as 41-71%.21 Pain in pancreatic cancer can 
be neuropathic in nature, especially where there 
is infiltration of the coeliac plexus and may require 
treatment with a combination of opioid and adjuvant 
analgesics (see figure 1).    
Recently the anticonvulsants gabapentin and pregabalin 
have been introduced in the management of neuropathic 
pain. Treatment failure with these agents may occur for 
different reasons. Pregabalin has been studied in pain 
due to chronic pancreatitis and its absorption profile is 
unaltered in this condition.22,23 However, it is not known 
whether alteration in gastrointestinal motility caused by 
opioids, which are commonly co-prescribed in cancer 
pain, has an affect upon the absorption of adjuvant 
analgesics, or whether PEI and its treatment influences 
the absorption of orally administered analgesics.  
When there is treatment failure with oral opioids, 
alternative routes of administration can be considered, 
such as transdermal, subcutaneous or intravenously. 
Patients can also be referred for consideration of 
an interventional procedure such as a coeliac plexus 
block. There is considerable regional variation in access 
to interventional pain specialists within Australia, and 
patients in rural locations may travel to a major tertiary 
referral centre for assessment. A recent Cochrane 
Collaboration review of coeliac plexus blocks for pain 
in advanced pancreatic cancer did not demonstrate 
a durable benefit in analgesia with this technique. 
However, there was an objective reduction in oral 
opioids taken by patients who underwent the procedure 
compared with those who were managed conservatively 
and they experienced fewer side-effects from opioid 
administration.24
Liver metastases
Advanced pancreatic cancer commonly metastasises to 
the liver, causing progressive liver failure with jaundice, 
ascites, lymphoedema and hepatic encephalopathy. 
Biliary stenting may be complicated by ascending 
cholangitis and this can require treatment with intravenous 
antibiotics or replacement of the biliary stent. It is known 
from private billing data from the United States that 
chemotherapy is more commonly delayed for patients 
who have plastic endoprosthetic stents than metallic 
stents, as plastic stents are more frequently blocked 
and colonised by bacteria than metallic stents.25,26 
It is worthwhile to consider replacement of a stent 
if colonisation is suspected.21,26 Pruritis occurs with 
jaundice, and treatment options with a variety of agents 
from different classes have been reported in clinical 
trials. These include rifampicin, cholestyramine and 
ondansetron.27 However, due to the small numbers of 
participants in studies considered in a Cochrane review 
on pruritis in palliative care, it was only possible for the 
Figure 1: Management of pain due to coeliac plexus infiltration.
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authors to recommend that good quality further studies 
are needed in this area.
Ascites can be a difficult symptom to manage. Successful 
treatment with diuretics such as spironolactone is 
enhanced when the intra-abdominal volume of ascites is 
relatively small by clinical evaluation, which is more likely 
at an early stage in the illness. More established ascites is 
likely to be refractory to diuretics, even with a combination 
of class agents, and ascitic drainage may be required.28 
In some centres this is done under radiological guidance. 
Where repeated abdominal paracentesis is required, 
permanent drains such as Tenckhoff catheter (peritoneal 
dialysis catheter) or tunneled PleurX drains can be used. 
The insertion of a drain of this type means that patients 
can be managed successfully at home without attending 
a hospital appointment or being admitted as an inpatient 
to have a procedure.29
Conclusion
Patients with pancreatic cancer often present with 
advanced disease, for which there are no curative 
options. There is evidence that conditions which co-exist 
in pancreatic cancer such as pain, depression, cachexia 
and pancreatic exocrine insufficiency are under-treated. 
A multi-disciplinary approach to management can have 
a positive impact on quality of life in a condition that is 
predicted to increase in prevalence over the next few 
decades and currently has limited options for disease 
modification.
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